论文部分内容阅读
[目的]探讨水飞蓟素联合阿霉素对人乳腺癌耐药细胞MCF-7/ADM耐药性的影响。[方法 ]采用MTT法测定单用阿霉素及其联合水飞蓟素对MCF-7/S、MCF-7/ADM细胞增殖抑制率(IR),计算耐药倍数和逆转倍数。[结果]阿霉素作用MCF-7/S的IC50值(2.89±0.35μg/ml)明显小于MCF-7/ADM(56.85±2.12μg/ml),耐药倍数为27.6倍;阿霉素联合水飞蓟素作用MCF-7/ADM的IC50值(9.07±0.56μg/ml)明显小于单独使用阿霉素(59.52±2.38μg/ml),逆转耐药倍数为6.6倍。[结论]人乳腺癌MCF-7/ADM细胞对阿霉素具有明确耐药性,水飞蓟素能够明显逆转MCF-7/ADM对阿霉素的耐药性。
[Objective] To investigate the effects of silymarin and doxorubicin on the drug resistance of human breast cancer cell line MCF-7 / ADM. [Method] MTT assay was used to determine the inhibitory rate (IR) of proliferation of MCF-7 / S and MCF-7 / ADM cells treated with doxorubicin alone and in combination with silymarin. [Result] The IC50 value of Adriamycin-treated MCF-7 / S (2.89 ± 0.35μg / ml) was significantly lower than that of MCF-7 / ADM (56.85 ± 2.12μg / ml) The IC50 value of MCF-7 / ADM with silymarin (9.07 ± 0.56μg / ml) was significantly lower than that with ADM alone (59.52 ± 2.38μg / ml). The IC50 of MCF-7 / ADM was 6.6 times. [Conclusion] Human breast cancer MCF-7 / ADM cells have definite drug resistance to doxorubicin. Silymarin can obviously reverse the resistance of doxorubicin to MCF-7 / ADM.